Tuesday, June 15, 2021

MissionIRNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Addition to Russell 2000, 3000 Indexes

 DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics (“DTx”) market, will be joining the broad-market Russell 3000(R) Index and the small-cap Russell 2000(R) Index at the conclusion of the Russell U.S. Indexes annual reconstitution, which will be effective after the U.S. equity markets open on Monday, June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021. The annual reconstitution of the Russell indexes identifies the 4,000 largest U.S. stocks as of May 7, 2021; it also ranks them by total market capitalization. Once a company joins the Russell 3000 Index, the membership lasts for one year, until the index conducts its annual reconstitution. Membership in the index also includes automatic inclusion in the large-cap Russell 1000(R) Index or small-cap Russell 2000 Index along with appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes by evaluating market-capitalization rankings and style attributes. “Inclusion in the Russell indexes reflects the hard work and achievements of the entire Dario team as we work to build the premier digital health and therapeutics company,” said DarioHealth CEO Erez Raphael in the press release. “We look forward to a heightened awareness of our company that inclusion in these widely-followed indexes confers.”

To view the full press release, visit https://ibn.fm/7po12

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html